Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas

NCT06124690 · tracked via the Priya Life Science Germany tracker

Sponsor

Robert Bosch Medical Center

Phase

Not applicable

Started

2023-09-01

Last updated

2024-12-18

Condition(s) studied

Persistent Atrial FibrillationCatheter AblationLow Voltage Areas

Investigational drug(s) / intervention(s)

Catheter ablation

Catheter ablation: Pulmonary vein isolation and ablation of low voltage areas.

Study summary

An effective therapy of persistent atrial fibrillation beyond pulmonary vein isolation remains unsatisfactory. Targeting endocardial low-voltage areas represents an approach of substrate modification.

This prospective, randomized study investigated the efficacy of ablation of low-voltage areas versus PVI and additional linear ablations in patients with persistent atrial fibrillation in terms of single-procedure arrhythmia-free outcome and safety.

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: * Persistent atrial fibrillation according to the current guidelines * Age \> 18 years * Patient information Exclusion Criteria: * Minors

Primary outcome measure(s)

Number of participants with atrial arrhythmia recurrence after 12 months follow-up — 12 months
Number of participants with atrial arrhythmia recurrence after 12 months follow-up

Trial sites (1)

Facility	City	Region	Status
Robert Bosch Health Coampus	Stuttgart	Baden-Wurttemberg

More Robert Bosch Medical Center trials in Germany

Evaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults. Recruiting

Other trials for the same condition

VOLT CE Mark Study Active, not recruiting

A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation Recruiting

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation Active, not recruiting

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation Active, not recruiting

STOP Persistent AF PAS Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06124690 on ClinicalTrials.gov ↗ ← All trials in Germany